Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
AbbVie Inc. is a global, research-driven biopharmaceutical company focused on the discovery, development, and commercialization of advanced therapies for serious and chronic diseases. The company operates primarily within the biopharmaceuticals industry, with core therapeutic areas spanning immunology, oncology, neuroscience, eye care, and virology. AbbVie’s revenues are largely driven by branded prescription medicines, with flagship products including Humira, Skyrizi, Rinvoq, Botox, and Venclexta, which serve large patient populations across autoimmune, cancer, and neurological conditions.
AbbVie was established in 2013 as a spin-off from Abbott Laboratories, becoming an independent publicly traded company following the separation of Abbott’s proprietary pharmaceutical business. Since its formation, AbbVie has pursued a strategy of combining internally developed medicines with targeted acquisitions to diversify beyond Humira and strengthen long-term growth. The company is widely recognized for its scale in immunology and for leveraging lifecycle management, global commercial infrastructure, and sustained R&D investment as strategic advantages.
Business Operations
AbbVie organizes its operations around major therapeutic segments, including Immunology, Oncology, Neuroscience, Eye Care, and Virology. The Immunology segment has historically been the largest revenue contributor, led by Humira and increasingly by newer-generation therapies Skyrizi and Rinvoq. Oncology revenues are supported by products such as Imbruvica (marketed in partnership with Johnson & Johnson following the acquisition of Pharmacyclics) and Venclexta (developed in collaboration with Roche). The Neuroscience and Eye Care segments were significantly expanded through the acquisition of Allergan, bringing in assets such as Botox Therapeutic and Botox Cosmetic.
The company generates revenue through direct pharmaceutical sales across domestic and international markets, supported by a global manufacturing and distribution network. AbbVie controls extensive proprietary technologies in biologics, small molecules, and advanced drug delivery, while maintaining multiple strategic collaborations and licensing agreements to supplement internal research. Wholly owned subsidiaries include Allergan plc and Pharmacyclics LLC, which operate as integral parts of AbbVie’s commercial and R&D platform.
Strategic Position & Investments
AbbVie’s strategic direction centers on sustaining growth through innovation, portfolio diversification, and global expansion of newer branded therapies. A key priority has been mitigating revenue concentration risk following U.S. Humira biosimilar competition by accelerating adoption of Skyrizi and Rinvoq, which the company positions as long-term growth drivers across multiple indications. AbbVie continues to invest heavily in late-stage clinical development, particularly in immunology, hematologic oncology, and neuroscience.
Major investments include the 2020 acquisition of Allergan, which broadened AbbVie’s exposure to aesthetics and neuroscience, and earlier acquisitions such as Pharmacyclics, which strengthened its oncology portfolio. AbbVie also maintains a robust pipeline supported by venture investments, research collaborations, and selective bolt-on acquisitions aimed at emerging modalities, including next-generation immunotherapies and neuropsychiatric treatments.
Geographic Footprint
AbbVie is headquartered in North America, with its corporate headquarters located in North Chicago, Illinois. The company maintains a significant presence across Europe, Asia-Pacific, Latin America, and other international markets, with commercial operations in more than 70 countries. The United States represents the largest single market, but international sales account for a substantial portion of total revenue, particularly in Western Europe and Japan.
Manufacturing, research, and commercial infrastructure are globally distributed, enabling AbbVie to support international clinical development and regulatory filings. Through both organic operations and acquired entities such as Allergan, AbbVie has established a broad global footprint that supports its ability to launch products simultaneously across major pharmaceutical markets.
Leadership & Governance
AbbVie’s leadership team emphasizes disciplined capital allocation, scientific innovation, and long-term value creation. The company’s governance framework reflects continuity from its origins as part of Abbott Laboratories, combined with an independent strategic vision focused on growth through R&D and strategic acquisitions.
Key executives include:
- Robert A. Michael – Chief Executive Officer
- Scott T. Reents – Chief Financial Officer
- Michael Severino, M.D. – Vice Chairman and President
- Roopal Thakkar, M.D. – Executive Vice President, Research & Development and Chief Scientific Officer
- Jeff Stewart – Chief Commercial Officer
- Robert Long – Executive Vice President, Operations
The leadership team collectively emphasizes pipeline depth, operational efficiency, and global access to innovative medicines as core elements of AbbVie’s long-term strategy.